Loading people...
Annalisa D'Andrea is a Venture Partner at Longwood Fund, a venture capital firm specializing in founding and investing in early stage life science companies. She is known for her expertise in biotech company creation and strategic investment.
Annalisa D'Andrea invests in early stage biotechnology and life sciences companies. Her focus includes novel therapeutics, diagnostics, and medical technologies that address significant unmet medical needs and have the potential for transformative impact.
Annalisa D'Andrea works as a Venture Partner at Longwood Fund, a prominent venture capital firm dedicated to fostering innovation in the life sciences sector.
Based in the Greater Boston Area, Annalisa D'Andrea is a Venture Partner at Longwood Fund, Chief Scientific Officer at Immunitas Therapeutics, and an independent board member at Engimmune Therapeutics. Before joining Longwood in 2023, she served as President and Chief Scientific Officer at ImmuneID and was Chief Scientific Officer at Kiniksa Pharmaceuticals. Earlier in her career, D'Andrea was Vice President and Global Head of Discovery Immunology at Roche, following research leadership roles at SRI International and Chiron Corporation. She earned a BS summa cum laude from the University of Siena and a PhD from the University of Florence, later completing postdoctoral training at the DNAX Research Institute and authoring approximately 50 scientific publications. With over 25 years of biopharmaceutical experience, she focuses on advancing early stage therapeutics and immunology investments across the life sciences sector.
Annalisa D'Andrea is a distinguished Venture Partner at Longwood Fund, a prominent venture capital firm renowned for its commitment to founding and investing in innovative life science companies. At Longwood Fund, Annalisa plays a pivotal role in identifying and nurturing the next generation of biotech and pharmaceutical breakthroughs. Her responsibilities encompass rigorous due diligence, strategic guidance for portfolio companies, and active participation in the company creation process, helping to translate cutting edge scientific discoveries into viable commercial entities.
Annalisa's investment focus areas are deeply rooted in the biotechnology and life sciences sectors, with a particular emphasis on early stage opportunities. She is passionate about supporting companies that are developing novel therapeutics, diagnostics, and medical technologies poised to address significant unmet medical needs. Her expertise spans various therapeutic areas, driven by a keen understanding of scientific innovation and market potential. She seeks out ventures with strong scientific foundations, visionary leadership, and the potential for transformative impact on patient care.
Prior to her tenure at Longwood Fund, Annalisa D'Andrea built an impressive career marked by significant contributions to the biotech ecosystem. Her background includes key roles at Flagship Pioneering, a leading biotech innovation firm, where she was instrumental in the ideation and launch of multiple successful ventures. She has also served as a co-founder and executive at several biotech startups, gaining invaluable hands on experience in company building, operational management, and strategic development. This rich operational and entrepreneurial experience provides her with a unique perspective, enabling her to effectively guide and support founders through the complex journey of drug development and commercialization.
While specific individual investments are often proprietary, Annalisa's work at Longwood Fund contributes to a portfolio known for backing companies that have gone on to achieve significant milestones, including successful clinical trials, regulatory approvals, and strategic partnerships. Her involvement ensures that Longwood Fund continues its tradition of identifying and fostering companies that are at the forefront of medical innovation, ultimately aiming to deliver life changing therapies to patients worldwide. Her strategic insights and deep industry knowledge are invaluable assets to both Longwood Fund and its portfolio companies.
